Table 1.
Study measures and outcomes to be collected
| Variable | Baseline | 10/12 weeks (post) | 3-month follow-up (22-weeks) |
6-month follow-up (36-weeks) |
12-month follow-up (62-weeks) |
|---|---|---|---|---|---|
| Primary outcomes | |||||
| 6 min walk distance (6MWD) | X | X | X | X | |
| Secondary outcomes | |||||
| 30s sit-to-stand test (30STS) | X | X | X | X | |
| Clinical COPD Questionnaire (CCQ) | X | X | X | X | |
| COPD Assessment Test (CAT) | X | X | X | X | |
| Hospital Anxiety Depression Scale | X | X | X | X | |
| EuroQol 5D (3-L) | X | X | X | X | |
| Other variables and outcomes | |||||
| Attendance in rehabilitation | X | ||||
| Number of COPD related hospital admissions | X | X | X | X | X |
| Number of COPD hospital days | X | X | X | X | X |
| COPD related outpatient visits | X | X | X | X | X |
| Number of COPD exacerbations | X | X | X | X | X |
| Mortality | X | X | X | X | X |
| Exploratory outcome | |||||
| 24 h–mobility (ActivePAL3tm; 5 days) | X | X | X | X | |
| Descriptive variables | |||||
| Lung function | X | X | |||
| FVC | X | X | |||
| FEV1 | X | X | |||
| FEV1/FVC% | X | X | |||
| FEV1% expected | X | X | |||
| Charlson morbity Index | X | X | |||
| Anthropometric measures | |||||
| Gender | X | ||||
| Age | X | ||||
| Weight | X | X | X | X | |
| Height | X | X | X | X | |
| Body Mass Index (BMI) | X | X | X | X | |
| Self-reported measures | |||||
| Smoking status | X | X | X | X | |
| Pharmacologic treatment | X | X | X | X | |